Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia.

Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Cherel M, Debord C, Le Bris Y, Theisen O, Mahé B, Dubruille V, Godon C, Robillard N, Wuilleme S, Touzeau C, Gastinne T, Blin N, Lok A, Bonnet A, Le Gouill S, Moreau P, Béné MC, Chevallier P.

Cytokine. 2019 Aug;120:85-87. doi: 10.1016/j.cyto.2019.04.015. Epub 2019 Apr 28.

PMID:
31035172
2.

FLT3 ligand plasma levels in acute myeloid leukemia.

Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Cherel M, Debord C, Le Bris Y, Theisen O, Mahé B, Dubruille V, Godon C, Robillard N, Wuilleme S, Touzeau C, Gastinne T, Blin N, Lok A, Bonnet A, Le Gouill S, Moreau P, Béné MC, Chevallier P.

Haematologica. 2019 Jun;104(6):e240-e243. doi: 10.3324/haematol.2018.209460. Epub 2019 Jan 10. No abstract available.

3.

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.

Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, Dejoie T, Maheo S, Stoppa AM, Pegourie B, Karlin L, Garderet L, Arnulf B, Doyen C, Meuleman N, Royer B, Eveillard JR, Benboubker L, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Kolb B, Fohrer C, Mohty M, Macro M, Richardson PG, Carlton V, Moorhead M, Willis T, Faham M, Anderson KC, Harousseau JL, Leleu X, Facon T, Moreau P, Attal M, Avet-Loiseau H, Munshi N.

Blood. 2018 Dec 6;132(23):2456-2464. doi: 10.1182/blood-2018-06-858613. Epub 2018 Sep 24.

PMID:
30249784
4.

CD200 expression in flow cytometry helps to distinguish mantle cell lymphoma from other CD5-positive B-cell neoplasms.

Debord C, Robillard N, Theisen O, Gastinne T, Godmer P, Graveleau J, Le Gouill S, Luycx O, Tiab M, Loirat M, Lestang E, Wuillème S, Godon C, Eveillard M, Béné MC.

Hematol Oncol. 2018 Apr 15. doi: 10.1002/hon.2511. [Epub ahead of print] No abstract available.

PMID:
29656538
5.

Diagnosis of a lymphoma associated with human herpes virus 8 aided by flow cytometric immunophenotyping.

Boutault R, Le Glaunec J, Debord C, Robillard N, Nicolet L, Eveillard M.

Br J Haematol. 2018 Feb;180(4):471. doi: 10.1111/bjh.14968. Epub 2018 Feb 1. No abstract available.

PMID:
29388203
6.

Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia.

Chevallier P, Chantepie S, Huguet F, Raffoux E, Thomas X, Leguay T, Marchand T, Isnard F, Charbonnier A, Maury S, Gallego-Hernanz MP, Robillard N, Guillaume T, Peterlin P, Garnier A, Rialland F, Le Houerou C, Goldenberg DM, Wegener WA, Béné MC, Dombret H.

Haematologica. 2017 May;102(5):e184-e186. doi: 10.3324/haematol.2016.159905. Epub 2017 Feb 2. No abstract available.

7.

Lymphocyte expansion after unrelated cord blood allogeneic stem cell transplantation in adults.

Le Bris Y, Guillaume T, Ménard A, Illiaquer M, Martin J, Malard S, Duquesne A, Peterlin P, Debord C, Robillard N, Eveillard M, Wuillème S, Delaunay J, Mohty M, Garnier A, Moreau P, Béné MC, Chevallier P.

Bone Marrow Transplant. 2017 Jun;52(6):854-858. doi: 10.1038/bmt.2016.364. Epub 2017 Jan 30.

PMID:
28134920
8.

A new mutation of ANO6 in two familial cases of Scott syndrome.

Boisseau P, Bene MC, Besnard T, Pachchek S, Giraud M, Talarmain P, Robillard N, Gourlaouen MA, Bezieau S, Fouassier M.

Br J Haematol. 2018 Mar;180(5):750-752. doi: 10.1111/bjh.14439. Epub 2016 Nov 23. No abstract available.

PMID:
27879994
9.

Assessment of tumoral plasma cells in apheresis products for autologous stem cell transplantation in multiple myeloma.

Wuillème S, Lok A, Robillard N, Dupuis P, Stocco V, Migné H, Dusquesne A, Touzeau C, Tiab M, Béné MC, Moreau P.

Bone Marrow Transplant. 2016 Aug;51(8):1143-5. doi: 10.1038/bmt.2016.74. Epub 2016 Apr 4. No abstract available.

PMID:
27042840
10.

Postoperative awake paralysis in the intensive care unit after cardiac surgery due to residual neuromuscular blockade: a case report and prospective observational study.

Roy M, Morissette N, Girard M, Robillard N, Beaulieu P.

Can J Anaesth. 2016 Jun;63(6):725-30. doi: 10.1007/s12630-016-0606-1. Epub 2016 Mar 2.

PMID:
26936365
11.

(90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study.

Chevallier P, Eugene T, Robillard N, Isnard F, Nicolini F, Escoffre-Barbe M, Huguet F, Hunault M, Marcais A, Gaschet J, Cherel M, Guillaume T, Delaunay J, Peterlin P, Eveillard M, Thomas X, Ifrah N, Lapusan S, Bodet-Milin C, Barbet J, Faivre-Chauvet A, Ferrer L, Bene MC, Le Houerou C, Goldenberg DM, Wegener WA, Kraeber-Bodéré F.

Lancet Haematol. 2015 Mar;2(3):e108-17. doi: 10.1016/S2352-3026(15)00020-4. Epub 2015 Feb 25.

PMID:
26687796
12.

Flow cytometry in hematological nonmalignant disorders.

Béné MC, Le Bris Y, Robillard N, Wuillème S, Fouassier M, Eveillard M.

Int J Lab Hematol. 2016 Feb;38(1):5-16. doi: 10.1111/ijlh.12438. Epub 2015 Nov 6. Review.

PMID:
26542092
13.

Major impact of an early bone marrow checkpoint (day 21) for minimal residual disease in flow cytometry in childhood acute lymphoblastic leukemia.

Eveillard M, Robillard N, Arnoux I, Garand R, Rialland F, Thomas C, Strullu M, Michel G, Béné MC, Fossat C, Loosveld M.

Hematol Oncol. 2017 Jun;35(2):237-243. doi: 10.1002/hon.2263. Epub 2015 Oct 9.

PMID:
26449287
14.

Ebola preparedness: a rapid needs assessment of critical care in a tertiary hospital.

Sarti AJ, Sutherland S, Robillard N, Kim J, Dupuis K, Thornton M, Mansour M, Cardinal P.

CMAJ Open. 2015 Apr 2;3(2):E198-207. doi: 10.9778/cmajo.20150025. eCollection 2015 Apr-Jun.

15.

CD180 expression in B-cell lymphomas: A multicenter GEIL study.

Mayeur-Rousse C, Guy J, Miguet L, Bouyer S, Geneviève F, Robillard N, Solly F, Maar A, Bené MC, Mauvieux L; GEIL (Groupe d'Etude Immunologique des Leucémies).

Cytometry B Clin Cytom. 2016 Sep;90(5):462-6. doi: 10.1002/cyto.b.21325. Epub 2015 Oct 6.

16.

Detection of phosphatidyl serine on activated platelets' surface by flow cytometry in whole blood: a simpler test for the diagnosis of Scott syndrome.

Halliez M, Fouassier M, Robillard N, Ternisien C, Sigaud M, Trossaert M, Bene MC.

Br J Haematol. 2015 Oct;171(2):290-292. doi: 10.1111/bjh.13391. Epub 2015 Mar 31. No abstract available.

PMID:
25823976
17.

Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study.

Chevallier P, Huguet F, Raffoux E, Etienne A, Leguay T, Isnard F, Robillard N, Guillaume T, Delaunay J, Charbonnier A, Pigneux A, Peterlin P, Bené MC, Wegener WA, Goldenberg DM, Dombret H.

Haematologica. 2015 Apr;100(4):e128-31. doi: 10.3324/haematol.2014.120220. Epub 2014 Dec 31. No abstract available.

18.

Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.

Fossat C, Roussel M, Arnoux I, Asnafi V, Brouzes C, Garnache-Ottou F, Jacob MC, Kuhlein E, Macintyre-Davi E, Plesa A, Robillard N, Tkaczuk J, Ifrah N, Dombret H, Béné MC, Baruchel A, Garand R; French Multicenter Study Groups for Pediatric and Adult ALL.

Cytometry B Clin Cytom. 2015 Jan;88(1):21-9. doi: 10.1002/cyto.b.21195. Epub 2014 Nov 1.

19.

Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.

Fossat C, Roussel M, Arnoux I, Asnafi V, Brouzes C, Garnache-Ottou F, Jacob MC, Kuhlein E, Macintyre-Davi E, Plesa A, Robillard N, Tkaczuk J, Ifrah N, Dombret H, Béné MC, Baruchel A, Garand R; for the French Multicenter Study Groups for Pediatric and Adult ALL.

Cytometry B Clin Cytom. 2014 Oct 1. doi: 10.1002/cytob.21195. [Epub ahead of print]

20.

Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.

Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L, Marit G, Moreau P, Pegourie B, Caillot D, Fruchart C, Stoppa AM, Gentil C, Wuilleme S, Huynh A, Hebraud B, Corre J, Chretien ML, Facon T, Avet-Loiseau H, Attal M.

J Clin Oncol. 2014 Sep 1;32(25):2712-7. doi: 10.1200/JCO.2013.54.8164. Epub 2014 Jul 14.

PMID:
25024076
21.

Immunophenotype of normal and myelomatous plasma-cell subsets.

Robillard N, Wuillème S, Moreau P, Béné MC.

Front Immunol. 2014 Mar 31;5:137. doi: 10.3389/fimmu.2014.00137. eCollection 2014.

22.

Pure Red Cell Aplasia with Adult Onset Still's Disease.

Robillard N, Nguyen PV, Wistaff R, Laskine M.

Case Rep Med. 2013;2013:308342. doi: 10.1155/2013/308342. Epub 2013 Sep 2.

23.

A single-tube multiparameter seven-colour flow cytometry strategy for the detection of malignant plasma cells in multiple myeloma.

Robillard N, Béné MC, Moreau P, Wuillème S.

Blood Cancer J. 2013 Aug 16;3:e134. doi: 10.1038/bcj.2013.33. No abstract available.

24.

BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principle.

Chevallier P, Bodet-Milin C, Robillard N, Eugene T, Menard A, Le Houerou C, Guillaume T, Delaunay J, Escoffre-Barbe M, Wegener WA, Goldenberg DM, Kraeber-Bodéré F.

Eur J Haematol. 2013 Dec;91(6):552-6. doi: 10.1111/ejh.12183. Epub 2013 Sep 12.

PMID:
23927500
25.

Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells.

Chiron D, Maïga S, Surget S, Descamps G, Gomez-Bougie P, Traore S, Robillard N, Moreau P, Le Gouill S, Bataille R, Amiot M, Pellat-Deceunynck C.

Blood Cancer J. 2013 Jun 7;3:e120. doi: 10.1038/bcj.2013.18.

26.

Characterization of various blood and graft sources: a prospective series.

Chevallier P, Robillard N, Illiaquer M, Esbelin J, Mohty M, Bodin-Bressollette C, Guillaume T, Stocco V, Auffray F, Derenne S, Planche L, Bene MC, Imbert-Marcille BM.

Transfusion. 2013 Sep;53(9):2020-6. doi: 10.1111/trf.12072. Epub 2013 Jan 16.

PMID:
23320942
27.

HHV-6 cell receptor CD46 expression on various cell subsets of six blood and graft sources: a prospective series.

Chevallier P, Robillard N, Illiaquer M, Esbelin J, Mohty M, Bodin-Bressollette C, Guillaume T, Stocco V, Auffray F, Derenne S, Planche L, Bene MC, Imbert-Marcille BM.

J Clin Virol. 2013 Apr;56(4):331-5. doi: 10.1016/j.jcv.2012.12.005. Epub 2013 Jan 1.

PMID:
23287444
28.

Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL.

Garand R, Beldjord K, Cavé H, Fossat C, Arnoux I, Asnafi V, Bertrand Y, Boulland ML, Brouzes C, Clappier E, Delabesse E, Fest T, Garnache-Ottou F, Huguet F, Jacob MC, Kuhlein E, Marty-Grès S, Plesa A, Robillard N, Roussel M, Tkaczuk J, Dombret H, Macintyre E, Ifrah N, Béné MC, Baruchel A.

Leukemia. 2013 Feb;27(2):370-6. doi: 10.1038/leu.2012.234. Epub 2012 Aug 16.

PMID:
23070018
29.

Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study.

Chevallier P, Robillard N, Charbonnier A, Raffoux E, Maury S, Carras S, Chabrot C, Fohrer C, Bernard M, Blade JS, Etienne A, Talmant P, Delaunay J, Guillaume T, Mohty M, Bene MC, Ifrah N, Dombret H.

Blood. 2012 Mar 15;119(11):2474-7. doi: 10.1182/blood-2011-11-390781. Epub 2012 Jan 20.

30.

Rituximab for the treatment of adult relapsed/refractory CD20 positive B-ALL patients: a pilot series.

Chevallier P, Pigneux A, Robillard N, Ayari S, Guillaume T, Delaunay J, Eveillard M, Dumas PY, Lippert E, Mohty M, Leguay T.

Leuk Res. 2012 Mar;36(3):311-5. doi: 10.1016/j.leukres.2011.11.010. Epub 2011 Dec 14.

PMID:
22172463
31.

Absence of JAK2-V617F in paroxysmal nocturnal haemoglobinuria-associated thrombosis.

Fouassier M, Girodon F, Cleyrat C, Robillard N, Garand R, Hermouet S.

Thromb Haemost. 2009 Jul;102(1):180-2. doi: 10.1160/TH09-03-0140. No abstract available.

PMID:
19572087
32.

Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease.

Chevallier P, Robillard N, Ayari S, Guillaume T, Delaunay J, Mechinaud F, Avet-Loiseau H, Mohty M, Harousseau JL, Garand R.

Br J Haematol. 2008 Dec;143(5):744-6. doi: 10.1111/j.1365-2141.2008.07153.x. No abstract available.

PMID:
19036018
33.

Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases.

Chevallier P, Robillard N, Houille G, Ayari S, Guillaume T, Delaunay J, Harousseau JL, Avet-Loiseau H, Mohty M, Garand R.

Leukemia. 2009 Apr;23(4):806-7. doi: 10.1038/leu.2008.303. Epub 2008 Oct 30. No abstract available.

PMID:
18971949
34.

Effector memory alphabeta T lymphocytes can express FcgammaRIIIa and mediate antibody-dependent cellular cytotoxicity.

Clémenceau B, Vivien R, Berthomé M, Robillard N, Garand R, Gallot G, Vollant S, Vié H.

J Immunol. 2008 Apr 15;180(8):5327-34.

35.

CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis.

Bataille R, Pellat-Deceunynck C, Robillard N, Avet-Loiseau H, Harousseau JL, Moreau P.

Leuk Res. 2008 Mar;32(3):379-82. Epub 2007 Sep 4.

PMID:
17767956
36.

Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.

Gomez-Bougie P, Wuillème-Toumi S, Ménoret E, Trichet V, Robillard N, Philippe M, Bataille R, Amiot M.

Cancer Res. 2007 Jun 1;67(11):5418-24.

37.

Reactive plasmacytoses can mimick plasma cell leukemia: therapeutical implications.

Touzeau C, Pellat-Deceunynck C, Gastinne T, Accard F, Jego G, Avet-Loiseau H, Robillard N, Harousseau JL, Bataille R, Moreau P.

Leuk Lymphoma. 2007 Jan;48(1):207-8. No abstract available.

PMID:
17325872
38.

Rituximab in CD20 positive multiple myeloma.

Moreau P, Voillat L, Benboukher L, Mathiot C, Dumontet C, Robillard N, Hérault O, Garnache F, Garand R, Varoqueaux N, Avet-Loiseau H, Harousseau JL, Bataille R; IFM group.

Leukemia. 2007 Apr;21(4):835-6. Epub 2007 Feb 1. No abstract available.

PMID:
17268523
39.

The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy.

Bataille R, Jégo G, Robillard N, Barillé-Nion S, Harousseau JL, Moreau P, Amiot M, Pellat-Deceunynck C.

Haematologica. 2006 Sep;91(9):1234-40. Review.

40.

CD45neg but not CD45pos human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a murine anti-IGF-1R monoclonal antibody, mAVE1642.

Descamps G, Wuillème-Toumi S, Trichet V, Venot C, Debussche L, Hercend T, Collette M, Robillard N, Bataille R, Amiot M.

J Immunol. 2006 Sep 15;177(6):4218-23.

41.

Histopathologically confirmed ocular rhinosporidiosis in two Canadians.

Harissi-Dagher M, Robillard N, Corriveau C, Mabon M, Allaire GS.

Can J Ophthalmol. 2006 Apr;41(2):226-9.

PMID:
16767214
42.

Quebec model for low vision rehabilitation.

Robillard N, Overbury O.

Can J Ophthalmol. 2006 Jun;41(3):362-6. Review.

PMID:
16767193
43.

Selection of Epstein-Barr virus specific cytotoxic T lymphocytes can be performed with B lymphoblastoid cell lines created in serum-free media.

Gallot G, Vollant S, Vivien R, Clémenceau B, Ferrand C, Tiberghien P, Gaschet J, Robillard N, Vié H.

Clin Exp Immunol. 2006 Apr;144(1):158-68.

44.

Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance.

Louis S, Braudeau C, Giral M, Dupont A, Moizant F, Robillard N, Moreau A, Soulillou JP, Brouard S.

Transplantation. 2006 Feb 15;81(3):398-407.

PMID:
16477227
45.

Lack of CD27 in myeloma delineates different presentation and outcome.

Moreau P, Robillard N, Jégo G, Pellat C, Le Gouill S, Thoumi S, Avet-Loiseau H, Harousseau JL, Bataille R.

Br J Haematol. 2006 Jan;132(2):168-70.

PMID:
16398651
46.

Four-color flow cytometry bypasses limitations of IG/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia.

Robillard N, Cavé H, Méchinaud F, Guidal C, Garnache-Ottou F, Rohrlich PS, Avet-Loiseau H, Garand R.

Haematologica. 2005 Nov;90(11):1516-23.

47.

A multiparametric flow cytometry method for detection of modifications of antigen expression in polymorphonuclear cells infected by human cytomegalovirus.

Bressollette-Bodin C, Andre-Garnier E, Robillard N, Billaudel S, Imbert-Marcille BM.

J Virol Methods. 2006 Mar;132(1-2):32-9. Epub 2005 Oct 3.

PMID:
16207497
48.

CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target.

Robillard N, Wuillème S, Lodé L, Magrangeas F, Minvielle S, Avet-Loiseau H.

Leukemia. 2005 Nov;19(11):2021-2. No abstract available.

PMID:
16167057
49.

CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity.

Bataille R, Robillard N, Avet-Loiseau H, Harousseau JL, Moreau P.

Haematologica. 2005 May;90(5):706-7.

50.

Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival.

Wuillème-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H, Harousseau JL, Amiot M, Bataille R.

Leukemia. 2005 Jul;19(7):1248-52.

PMID:
15902294

Supplemental Content

Loading ...
Support Center